BENITEC BIOPHARMA INC (BNTC)

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients...

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene...

Benitec Biopharma files for $125M mixed securities shelf (NASDAQ:BNTC)

Learn about the prospectus filed by Benitec Biopharma for the offer and sale of mixed securities, up to $125,000,000.

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First...

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene...

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma, a genetic medicines company, releases updates on OPMD program and other corporate and financial updates....

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related...

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene...

Benitec Biopharma prices $30M equity offering (NASDAQ:BNTC)

Benitec Biopharma (BNTC) priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares.The offering is expected to close on August...

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene...

Why Novavax Stock Zoomed 13% Higher on Monday

A renewed fight against COVID-19 might be coming.

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene...

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Dosing of the first subject with BB-301 is expected in the second half of 2023, following the rollover of subjects currently enrolled in the ongoing...

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

9 subjects enrolled into the OPMD clinical development program...

Benitec Biopharma to Present at the OPMD International Conference

9 OPMD subjects are now enrolled on the Natural History (NH) Study...